Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PuraPharm Corp. Ltd. ( (HK:1498) ) has issued an announcement.
PuraPharm Corporation Limited has strengthened its corporate governance structure with the appointment of Mr. Lee Stephen and Prof. Ng Wang Wai Charles as independent non-executive directors, effective 27 April 2026. Both will also serve on the audit, remuneration and nomination committees, expanding independent oversight of the company’s financial reporting, executive pay and board appointments.
Mr. Lee brings decades of experience in Asian private equity, corporate finance and infrastructure project management, having served as partner and managing director at AIF Capital since 1994. The board has confirmed his independence under Hong Kong listing rules, underscoring PuraPharm’s effort to bolster compliance, enhance board diversity of expertise and reassure investors on governance standards as the group navigates regional growth opportunities.
More about PuraPharm Corp. Ltd.
PuraPharm Corporation Limited is a Hong Kong-listed company focused on traditional Chinese medicine and related healthcare products, operating through subsidiaries across Asian markets. The group targets consumers seeking integrated herbal and modern medical solutions, positioning itself within the broader health and wellness sector in Greater China and beyond.
Average Trading Volume: 227,865
Technical Sentiment Signal: Sell
Current Market Cap: HK$157.8M
Learn more about 1498 stock on TipRanks’ Stock Analysis page.